|
|
Profile
|
Delegates :
Rocky H. Kato |
|
Incorporated :
August 11 , 2003 |
Paid in Capital :
100 Million yen |
Employees :
18 人 |
Address :
4-2-1 Wakahagi, Inzai, Chiba, 270-1609 Japan CHIBA
〒2701609
|
TEL/FAX :
+81-476-98-3471 / +81-476-98-3472 |
URL：
http://www.cell-able.com |
Attachment :
|
Mission/Background :
Transparent Inc. (TRP) was founded as a spin off venture from the Tokyo University of Science in August 2003.
TRP licensed in the patented technology 'cell culture array system’ from Dr. Kazunori Kataoka, a founder and a scientific advisor of TRP as well as a professor of the University of Tokyo.
A 3 dimensional cell culture system; Cell-able(TM) was launched in May 2008. Over 70 pharmaceutical and academic institutions are using Cell-able(TM) as of today.
TRP and Molecular Response in San Diego signed key collaboration and supply agreement to launch novel ex-vivo 3D cell culture system focused on oncology applications in April 2012.
|
|
Technology & Business
|
Transparent Inc. (TRP) is a leader in 3D cell culture plate design and applications supported by comprehensive patent portfolio in biomaterial sciences.
The 3 dimensional cell culture system; Cell-able(TM), based on photosensitive polymer technology and cell biological technology, creates in vivo environment on multi-well plates.
The system is applied to patient derived tumor cells, iPS cells, hepatocytes and other cells, and provides advanced cell culture models to develop new drugs and/or therapeutics.
TRP and Molecular Response (MRL) jointly introduced a novel 3 dimensional cell culture system based on TRP’s patented 3D cell culture plate design and manufacturing technologies, and MRL’s proprietary bank of ‘living’ tumor cells and quantitative high content platforms.
The platform will be marketed under TRP’s “Cell-able(TM) Oncology” brand with key contract research support for preclinical and clinical trial applications by MRL.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Cell-able(TM)
|
Launched
|
Available for 384, 96, 24, 12-well format and applied to tumor cells, iPS cells, hepatocytes and other cells
|
Improving usability’s depend on research objectives
|
Cell able(TM) Oncology
|
Launched
|
Available for 384, 96-well format and applied to any kind of tumor cells
|
Improving usability’s depend on research objectives
|
Pharmaceutical services using the world largest bank of tumor cells
|
Launched
|
Drug response and other research services using the bank of over 144,000 patient derived tumor cells
|
Establish a bank of patient derived tumor cells in Japan
|
|
|
|
|
|
|
|
|
|
Highlights
|
Cell-able(TM) Oncology allows primary tumor cells to grow in 3 dimensional cultures that more closely resemble in vivo like conditions.
Models grown in 3 dimensional culture conditions coupled with molecular characterization provide a stronger correlation to clinical outcomes than conventional preclinical anticancer drug testing.
|
|
Hot news
|
Cell-able(TM) Oncology and Pharmaceutical Services using the world largest bank of living tumor cells are available.
Plan to make 2 presentations of oncology and hepatocyte researches at the 27th JSSX in Funabori, Tokyo from November 20 to 22.
|
|
Alliance strategy
|
Transparent Inc. (TRP) is looking for partners for jointly developing new assay models and/or applications in order to contribute pharmaceutical researchers and medical professionals.
TRP is promoting collaborative oncology researches with institutions/hospitals in the world, and looking for partners in this field as well.
|
|
|